BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 50.2% within the second quarter, in keeping with its most up-to-date 13F submitting with the Securities and Change Fee. The fund owned 1,131,294 shares of the biopharmaceutical firm’s inventory after promoting 1,140,241 shares through the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Bristol-Myers Squibb had been price $46,983,000 as of its most up-to-date submitting with the Securities and Change Fee.
Numerous different institutional traders and hedge funds additionally lately purchased and bought shares of BMY. Traynor Capital Administration Inc. boosted its place in Bristol-Myers Squibb by 2.8% through the 1st quarter. Traynor Capital Administration Inc. now owns 7,672 shares of the biopharmaceutical firm’s inventory price $416,000 after buying a further 207 shares through the interval. Newbridge Monetary Companies Group Inc. lifted its place in shares of Bristol-Myers Squibb by 12.8% within the first quarter. Newbridge Monetary Companies Group Inc. now owns 1,910 shares of the biopharmaceutical firm’s inventory price $104,000 after buying a further 216 shares within the final quarter. Bfsg LLC boosted its holdings in shares of Bristol-Myers Squibb by 24.4% through the first quarter. Bfsg LLC now owns 1,120 shares of the biopharmaceutical firm’s inventory price $61,000 after buying a further 220 shares through the interval. Paragon Capital Administration LLC grew its place in Bristol-Myers Squibb by 1.1% through the first quarter. Paragon Capital Administration LLC now owns 20,500 shares of the biopharmaceutical firm’s inventory valued at $1,112,000 after buying a further 222 shares within the final quarter. Lastly, OmniStar Monetary Group Inc. elevated its stake in Bristol-Myers Squibb by 1.7% within the 2nd quarter. OmniStar Monetary Group Inc. now owns 13,316 shares of the biopharmaceutical firm’s inventory valued at $553,000 after shopping for a further 224 shares through the interval. 76.41% of the inventory is owned by institutional traders and hedge funds.
Bristol-Myers Squibb Inventory Efficiency
NYSE:BMY opened at $49.95 on Friday. The agency has a market capitalization of $101.25 billion, a PE ratio of -16.11, a PEG ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a 1 12 months low of $39.35 and a 1 12 months excessive of $63.03. The corporate has a present ratio of 1.16, a fast ratio of 0.99 and a debt-to-equity ratio of two.86. The agency’s fifty day easy transferring common is $45.01 and its 200 day easy transferring common is $46.59.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) final posted its quarterly earnings information on Friday, July twenty sixth. The biopharmaceutical firm reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a constructive return on fairness of 12.51% and a detrimental web margin of 14.06%. The enterprise had income of $12.20 billion for the quarter, in comparison with analyst estimates of $11.54 billion. Throughout the identical interval within the earlier 12 months, the corporate posted $1.75 earnings per share. The agency’s income for the quarter was up 8.7% on a year-over-year foundation. On common, sell-side analysts anticipate that Bristol-Myers Squibb will put up 0.77 EPS for the present 12 months.
Bristol-Myers Squibb Declares Dividend
The enterprise additionally lately disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of file on Friday, July fifth had been paid a $0.60 dividend. The ex-dividend date was Friday, July fifth. This represents a $2.40 annualized dividend and a dividend yield of 4.80%. Bristol-Myers Squibb’s payout ratio is -77.42%.
Analysts Set New Worth Targets
BMY has been the topic of quite a few analysis experiences. TD Cowen lifted their goal value on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the corporate a “maintain” ranking in a analysis observe on Monday, August twelfth. Jefferies Monetary Group boosted their goal value on Bristol-Myers Squibb from $49.00 to $51.00 and gave the corporate a “maintain” ranking in a analysis observe on Wednesday. StockNews.com raised Bristol-Myers Squibb from a “purchase” ranking to a “strong-buy” ranking in a analysis observe on Monday, July twenty ninth. Cantor Fitzgerald reissued a “impartial” ranking and issued a $45.00 value goal on shares of Bristol-Myers Squibb in a analysis observe on Monday, July twenty second. Lastly, Deutsche Financial institution Aktiengesellschaft reduce their value goal on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “maintain” ranking on the inventory in a analysis report on Tuesday, July twenty third. Two funding analysts have rated the inventory with a promote ranking, 13 have issued a maintain ranking, two have issued a purchase ranking and one has issued a robust purchase ranking to the corporate’s inventory. Primarily based on information from MarketBeat, the corporate has a consensus ranking of “Maintain” and a mean value goal of $54.67.
Get Our Newest Analysis Report on Bristol-Myers Squibb
About Bristol-Myers Squibb
Bristol-Myers Squibb Firm discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical merchandise worldwide. It affords merchandise for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience illnesses. The corporate’s merchandise embrace Eliquis for discount in threat of stroke/systemic embolism in non-valvular atrial fibrillation, and for the remedy of DVT/PE; Opdivo for numerous anti-cancer indications, together with bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, abdomen and esophageal most cancers; Pomalyst/Imnovid for a number of myeloma; Orencia for lively rheumatoid arthritis and psoriatic arthritis; and Sprycel for the remedy of Philadelphia chromosome-positive power myeloid leukemia.
Featured Articles
Need to see what different hedge funds are holding BMY? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Obtain Information & Scores for Bristol-Myers Squibb Every day – Enter your e mail tackle under to obtain a concise every day abstract of the newest information and analysts’ rankings for Bristol-Myers Squibb and associated firms with MarketBeat.com’s FREE every day e mail publication.
